Blog | HemaCare

IL-21 Strikes Twice: a Two-in-One Therapy for Aggressive non-Hodgkin Lymphoma

Dec 14, 2015 1:00:07 PM / by Dalia Gaddis posted in IL-21, Cancer Immunology, cancer immunotherapy, clinical trials, non-hodgkin lymphoma, research, T Cells

0 Comments

IL-21 has dual anti-tumor effects in mantle cell lymphoma, offering new hopes for a better therapy.

Since the signing of the National Cancer Act in 1971, the medical field has achieved significant progress in finding cures for certain types of cancer. Therapies against breast cancer and childhood leukemia have undergone major advances in the past four decades. However, when it comes to non-Hodgkin lymphoma (NHL), the struggle is still loud and clear. More than 60,000 Americans are diagnosed with NHL each year and the current estimates are 30% of these cases will not survive the disease.1

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts